1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Corcept’s Coup De GRACE

 
• By Elizabeth Cairns

The follow-on Cushing’s product relacorilant has hit in Phase III, and is forecast to lead the market – eventually.    

Red darts are placed in the center of the plate for darts and evening lights, a concept of targeting for business success.
• Source: Shutterstock

With sales of Korlym (mifepristone), the leading Cushing’s disease drug, forecast to start falling next year, Corcept Therapeutics Incorporated  needs a new money-spinner. Thanks to a hit in the pivotal GRACE trial, it appears to have one in relacorilant.

Key Takeaways
  • The GRACE trial of Corcept Therapeutics’ Cushing’s disease candidate relacorilant has succeeded in its pivotal trial.

Relacorilant, like its predecessor, aims to treat Cushing’s by modulating cortisol levels by competing with it at the glucocorticoid receptor....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D